Pre-made Mogamulizumab biosimilar ( Whole mAb, anti-CCR4 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-354
Anti-CCR4 therapeutic antibody (Pre-made Mogamulizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4). The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease. It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refractory CCR4+ cutaneous T cell lymphoma (CTCL). The latter approval was based on study with 28 subjects.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CCR4 therapeutic antibody (Pre-made Mogamulizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Amgen;Bristol-Myers Squibb;Kagoshima University Dental School;Kyowa Hakko;Kyowa Hakko Kirin;Ono Pharmaceutical|
|Conditions Approved||Adult T-cell leukaemia-lymphoma;Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Mycosis fungoides;Sezary syndrome;Mycosis fungoides|
|Conditions Active||Spinal cord disorders|
|Conditions Discontinued||Non-small cell lung cancer;Asthma;Hypersensitivity;Solid tumours|
|Development Tech||POTELLIGENT Technology|